本システムでは、JavaScriptを利用しています。JavaScriptを有効に設定してからご利用ください。
Skip to main content
Contact Us
Accessibility
LANGUAGE
JP
EN
HOME
About ASKA Pharmaceutical Holdings
Top Message
Corporate Philosophy
Company Overview
Charter of Corporate Behavior
Board Members and Corporate Officers
Company Information
Group Companies
Business Activities
Corporate Message
Digital Transformation
ASKA Pharmaceutical Holdings in Numbers
For Our Shareholders and Investors
Top Message
IR News
IR Library
IR Calendar
Management Strategies and Policies
Governance
Financial Highlights
ASKA Pharmaceutical Holdings at a glance
IR Related Information
Stock and Shareholder Information
Sustainability
Our Sustainability
Environmental
Social
Governance (Related Link)
ESG Chart and ESG Data Book
External Evaluation
Initiatives and Member Organizations
Third-party Opinion
Sustainability News
Various Contrasting Tables
Policies (Related Link)
Integrated Report (Related Link)
Press Releases
Contact Us
Privacy Policy
Basic Policy on the Proper Handling of Specific Personal Information, etc.
Terms of Use
Web Accessibility Policy
SNS Community Guidelines
Official website and SNS
Sitemap
Search Results
Important Notice
About ASKA Pharmaceutical Holdings
Company Overview
Group Companies
Top Message
Corporate Philosophy
Charter of Corporate Behavior
Board Members and Corporate Officers
Company Information
Business Activities
Corporate Message
Digital Transformation
ASKA Pharmaceutical Holdings in Numbers
For Our Shareholders and Investors
Top Message
Management Strategies and Policies
IR News
IR Library
IR Calendar
Governance
Financial Highlights
ASKA Pharmaceutical Holdings at a glance
IR Related Information
Stock & Shareholder Information
Sustainability
Integrated Report (Related links)
Our Basic Policy for Sustainability
Various Contrasting Tables
Our Sustainability
Top Commitment
Our Basic Policy for Sustainability
Materiality
Value Creation Process
Capital and Strengths
Initiatives for Sustainability and SDGs
Importance of Female Healthcare and Social Issues
Disclosures based on TCFD recommendations
Disclosures based on TNFD recommendations
Environmental
Governance (Related links)
External Evaluation
Third-party Opinion
Various Contrasting Tables
Integrated Report (Related links)
Social
ESG Chart and ESG Data Book
Initiatives and Member Organizations
Sustainability News
Policies (Related links)
HOME
>
HOME
>
For Our Shareholders and Investors
>
Financial Highlights
>
Financial Statements
>
Consolidated Balance Sheets
Consolidated Balance Sheets
PRINT
Consolidated Balance Sheets
Consolidated Statements of Income
Consolidated Statements of Cash Flows
[Based on Japanese GAAP]
Consolidated Balance Sheets
(Unit: millions of yen)
As of March 31, 2025
As of March 31, 2026
Assets
Current assets
Cash and deposits
10,603
10,126
Accounts receivable - trade
15,184
16,022
Securities
555
893
Merchandise and finished goods
15,041
14,743
Work in process
544
416
Raw materials and supplies
11,032
14,022
Other
5,423
5,265
Allowance for doubtful accounts
(94)
(67)
Total current assets
58,290
61,424
Non-current assets
Property, plant and equipment
Buildings and structures
11,708
12,654
Accumulated depreciation
(6,610)
(6,978)
Buildings and structures, net
5,097
5,676
Machinery, equipment and vehicles
17,168
18,040
Accumulated depreciation
(15,047)
(15,612)
Machinery, equipment and vehicles, net
2,121
2,428
Land
4,255
4,186
Construction in progress
6,508
6,078
Other
3,941
4,542
Accumulated depreciation
(3,258)
(3,667)
Other, net
683
874
Total property, plant and equipment
18,667
19,244
Intangible assets
Goodwill
2,611
2,354
Other
7,602
6,514
Total intangible assets
10,213
8,869
Investments and other assets
Investment securities
12,666
17,299
Deferred tax assets
2,312
2,085
Retirement benefit asset
-
647
Other
2,162
2,827
Allowance for doubtful accounts
(17)
(17)
Total investments and other assets
17,123
22,841
Total non-current assets
46,004
50,955
Total assets
104,295
112,379
(Unit: millions of yen)
As of March 31, 2025
As of March 31, 2026
Liabilities
Current liabilities
Accounts payable - trade
6,411
5,288
Electronically recorded obligations - operating
2,735
2,270
Short-term borrowings
2,521
1,707
Current portion of long-term borrowings
1,940
1,562
Accounts payable - other
6,194
6,446
Income taxes payable
173
1,574
Provision for bonuses
1,210
1,250
Provision for bonuses for directors (and other officers)
73
66
Other
1,617
2,124
Total current liabilities
22,879
22,291
Non-current liabilities
Long-term borrowings
6,441
8,165
Retirement benefit liability
206
23
Other
2,952
5,080
Total non-current liabilities
9,601
13,268
Total liabilities
32,480
35,559
Net assets
Shareholders' equity
Share capital
1,197
1,197
Capital surplus
-
31
Retained earnings
59,545
63,352
Treasury shares
(704)
(658)
Total shareholders' equity
60,039
63,923
Accumulated other comprehensive income
Valuation difference on available-for-sale securities
4,853
5,646
Foreign currency translation adjustment
-
(292)
Remeasurements of defined benefit plans
417
1,083
Total accumulated other comprehensive income
5,271
6,437
Non-controlling interests
6,504
6,459
Total net assets
71,814
76,819
Total liabilities and net assets
104,295
112,379
Consolidated Statements of Cash Flows
Consolidated Statements of Income
About ASKA Pharmaceutical Holdings
Top Message
Corporate Philosophy
Company Overview
Charter of Corporate Behavior
Board Members and Corporate Officers
Company Information
Company Information
Organization Chart
Corporate History
Access Map
Policies
Video Library
Media Library
Group Companies
Business Activities
Corporate Message
Digital Transformation
ASKA Pharmaceutical Holdings in Numbers
For Our Shareholders and Investors
Top Message
IR News
IR Library
IR Library
Financial Results and IR Events
Annual Securities Report
Integrated Report
Fact Sheet
Corporate Governance Report (Japanese version only, Related links)
Internal Control Report (Japanese version only, Related links)
Stock and Shareholder Information (Related links)
IR Calendar
Management Strategies and Policies
Management Strategies and Policies
Long-Term Vision ASKA VISION 2035
Medium-Term Management Plan
Pipeline and Intellectual Property
Business Risks
Disclosure Policy
IR Basic Policy
Disclaimer
Governance
Governance
Basic Principles / Corporate Governance Structure
Corporate Governance Basic Policy
Corporate Governance Report (Japanese version only)
Board Members
Compliance / Risk Management
Internal Control System
Internal Control Report (Japanese version only)
Dialogue with Shareholders
Message from Outside Directors
Financial Highlights
Financial Highlights
Performance Review
Performance Highlights
Financial Conditions
Financial Statements
Consolidated Balance Sheets
Consolidated Statements of Income
Consolidated Statements of Cash Flows
Earnings Forecast
ASKA Pharmaceutical Holdings at a glance
ASKA Pharmaceutical Holdings at a glance
Point1 About ASKA - Understanding & History -
Point2 About ASKA - Our Strengths -
Point3 Highly Specialized Product Lineup
Point4 Continuously Evolving R&D
Point5 Stable Shareholder Returns
Frequently Asked Questions
Business Model
ASKA's Management Strategy
Medicine & Body Glossary
IR seminar for Individual Investors
IR Related Information
IR Related Information
IR E-mail Newsletter Service
IR Site Map
Recommended Route to Access Our IR Website
How to Use the IR Site
IR Inquiries
External Evaluation (IR)
Stock and Shareholder Information
Stock and Shareholder Information
Stock Summary Information
Shareholder Information
Shareholders' Meeting
Stock Price Information
Shareholder Return
Stock Procedures (Japanese version only)
Articles of Incorporation and Stock Handling Regulations
Analyst Coverage
Corporate Bonds and Ratings Information
Shareholder Newsletters (Japanese version only)
Privacy Policy (Shareholders)
Sustainability
Our Sustainability
Our Sustainability
Top Commitment
Our Basic Policy for Sustainability
Materiality
Value Creation Process
Capital and Strengths
Initiatives for Sustainability and SDGs
Importance of Female Healthcare and Social Issues
Disclosures based on TCFD recommendations
Disclosures based on TNFD recommendations
Environmental
Environmental
Environmental Management
Disclosures Based on TCFD Recommendations
Disclosures based on TNFD recommendations
Decarbonization Initiatives
Initiatives for Water Resource
Initiatives for Recycle-Oriented Society and Biodiversity
Social
Social
Stakeholder Engagement
Respect for Human Rights
Human capital/Labour Practices
Diversity & Inclusion
Initiatives to Promote the Advancement of Women
Health Management Initiatives
Ethics and Compliance
Supply Chain
Customer Health and Safety
Social Contribution Activities(Community Involvement and Development)
Multi-Stakeholder Policy
Governance (Related Link)
ESG Chart and ESG Data Book
External Evaluation
Initiatives and Member Organizations
Third-party Opinion
Sustainability News
Various Contrasting Tables
Policies (Related Link)
Integrated Report (Related Link)
Press Releases
Contact Us
Privacy Policy
Basic Policy on the Proper Handling of Specific Personal Information, etc.
Terms of Use
Web Accessibility Policy
SNS Community Guidelines
Official website and SNS
Sitemap
Search Results
Important Notice
TOP